Niki BioSolutions, Inc.: 5%+ holders

As of November 7, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Niki BioSolutions, Inc. The largest reported stake is Kira S. Sheinerman's, at 51.56%. One filing is on record since July 24, 2026 (Schedule 13D, July 24, 2026).

2 more records on Niki BioSolutions, Inc. ↓

Sell to companies like Niki BioSolutions, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-07-24 · Reporting person: Kira S. Sheinerman · Sole voting: 1,515,016 · Shared voting: 277 · Sole dispositive: 1,515,016 · Shared dispositive: 277 · SCHEDULE 13D, 2026-07-24
• Filed 2026-07-24 · Holder: Kira S. Sheinerman · Percent: 51.56% · SCHEDULE 13D
• Event date 2026-07-20 · Holder: Kira S. Sheinerman · Percent: 51.56% · Shares: 1,515,293 · SCHEDULE 13D

Niki BioSolutions, Inc. has 1 Schedule 13D or 13G filing on record since 2026-07-24. 1 holder's latest filing reports 5% or more of common stock, par value $0.0001. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Niki BioSolutions, Inc. and the warning signs.

See Niki BioSolutions, Inc.'s free Snapshot Watch Niki BioSolutions, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Niki BioSolutions, Inc. and the records around it.

Niki BioSolutions, Inc. elsewhere on the record

• Leadership changes Sep 2026
• Who owns it

Want the whole picture on Niki BioSolutions, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Niki BioSolutions, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Niki BioSolutions, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   3 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Niki BioSolutions, Inc. by CUSIP 653942102 and gives its principal executive office as 116 Village Boulevard, Suite 200, Princeton, NJ 08540 (SCHEDULE 13D, 2026-07-24).

Source of funds (Item 3)

No funds or other consideration were used by the Reporting Person to acquire the shares of Common Stock reported herein. Such shares were issued to the Reporting Person solely as non-cash merger consideration in exchange for shares of common stock of DiamiR Biosciences Corp. previously held by the Reporting Person, pursuant to the Agreement and Plan of Merger, dated July 14, 2025, by and among Aptorum Group Limited, DiamiR Biosciences Corp. and the other parties thereto.Kira S. Sheinerman, SCHEDULE 13D, 2026-07-24

Purpose of Transaction (Item 4)

Kira S. Sheinerman

The information set forth in Items 3 and 6 is incorporated herein by reference. The shares of Niki Common Stock reported herein were acquired by the Reporting Person solely as merger consideration pursuant to the merger agreement, as described in Item 3 above. No funds or other consideration were expended by the Reporting Person in connection with the receipt of such shares. On July 20, 2026, the merger was consummated pursuant to the merger agreement. In connection with the merger, Aptorum effected the domestication and became a Delaware corporation, changing its name to Niki BioSolutions, Inc. The Niki Common Stock is listed on the Nasdaq Capital Market under the ticker symbol "NIKI" (CUSIP: 653942102). The Reporting Person is a party to that certain Stockholders Agreement, the final form of which is filed as Exhibit 4.5 hereto, which governs certain rights and obligations of the Reporting Person with respect to the Niki Common Stock. Reference is made to the Stockholders Agreement for a complete description of its terms, which are incorporated herein by reference.Item 4 of the SCHEDULE 13D filed 2026-07-24

Timeline

Swipe the table sideways to see every column.

Also on the record for Niki BioSolutions, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Niki BioSolutions, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Niki BioSolutions, Inc. is mentioned again
• Find former Niki BioSolutions, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes